ZVRA Valuation

Zevra Therapeutics Inc

Add to Watchlist

Advanced Chart

8.810

-0.28(-3.080%)1D

ZVRA Relative Valuation

ZVRA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ZVRA is overvalued; if below, it's undervalued.

Historical Valuation

Zevra Therapeutics Inc (ZVRA) is now in the Fair zone, suggesting that its current forward PS ratio of 8.81 is considered Fairly compared with the five-year average of -4.92. The fair price of Zevra Therapeutics Inc (ZVRA) is between 4.14 to 16.07 according to relative valuation methord.

Relative Value

Fair Zone

4.14-16.07

Current Price：8.81

Fair

22.17

Trailing

Forward

12.74

EV/EBITDA

Zevra Therapeutics Inc. (ZVRA) has a current EV/EBITDA of 12.74. The 5-year average EV/EBITDA is -3.51. The thresholds are as follows: Strongly Undervalued below -54.22, Undervalued between -54.22 and -28.86, Fairly Valued between 21.84 and -28.86, Overvalued between 21.84 and 47.20, and Strongly Overvalued above 47.20. The current Forward EV/EBITDA of 12.74 falls within the Historic Trend Line -Fairly Valued range.

11.05

EV/EBIT

Zevra Therapeutics Inc. (ZVRA) has a current EV/EBIT of 11.05. The 5-year average EV/EBIT is 1332.77. The thresholds are as follows: Strongly Undervalued below -31597.60, Undervalued between -31597.60 and -15132.41, Fairly Valued between 17797.95 and -15132.41, Overvalued between 17797.95 and 34263.14, and Strongly Overvalued above 34263.14. The current Forward EV/EBIT of 11.05 falls within the Historic Trend Line -Fairly Valued range.

8.81

Zevra Therapeutics Inc. (ZVRA) has a current PS of 8.81. The 5-year average PS is 9.63. The thresholds are as follows: Strongly Undervalued below -5.28, Undervalued between -5.28 and 2.18, Fairly Valued between 17.08 and 2.18, Overvalued between 17.08 and 24.54, and Strongly Overvalued above 24.54. The current Forward PS of 8.81 falls within the Historic Trend Line -Fairly Valued range.

11.30

P/OCF

Zevra Therapeutics Inc. (ZVRA) has a current P/OCF of 11.30. The 5-year average P/OCF is -3.17. The thresholds are as follows: Strongly Undervalued below -15.11, Undervalued between -15.11 and -9.14, Fairly Valued between 2.80 and -9.14, Overvalued between 2.80 and 8.77, and Strongly Overvalued above 8.77. The current Forward P/OCF of 11.30 falls within the Strongly Overvalued range.

12.43

P/FCF

Zevra Therapeutics Inc. (ZVRA) has a current P/FCF of 12.43. The 5-year average P/FCF is -2.60. The thresholds are as follows: Strongly Undervalued below -30.85, Undervalued between -30.85 and -16.73, Fairly Valued between 11.52 and -16.73, Overvalued between 11.52 and 25.64, and Strongly Overvalued above 25.64. The current Forward P/FCF of 12.43 falls within the Overvalued range.

Zevra Therapeutics Inc (ZVRA) has a current Price-to-Book (P/B) ratio of 3.72. Compared to its 3-year average P/B ratio of 5.10 , the current P/B ratio is approximately -27.11% higher. Relative to its 5-year average P/B ratio of 3.72, the current P/B ratio is about -0.13% higher. Zevra Therapeutics Inc (ZVRA) has a Forward Free Cash Flow (FCF) yield of approximately -4.89%. Compared to its 3-year average FCF yield of -13.47%, the current FCF yield is approximately -63.73% lower. Relative to its 5-year average FCF yield of -7.93% , the current FCF yield is about -38.36% lower.

3.72

P/B

Median3y

5.10

Median5y

3.72

-4.89

FCF Yield

Median3y

-13.47

Median5y

-7.93

Competitors Valuation Multiple

The average P/S ratio for ZVRA's competitors is 10.47, providing a benchmark for relative valuation. Zevra Therapeutics Inc Corp (ZVRA) exhibits a P/S ratio of 8.81, which is -15.83% above the industry average. Given its robust revenue growth of 605.36%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ZVRA.O

Zevra Therapeutics Inc

Rigel Pharmaceuticals Inc

Akebia Therapeutics Inc

CytomX Therapeutics Inc

Kalvista Pharmaceuticals Inc

10.78

544.64M

Performance Decomposition

Market capitalization of ZVRA decreased by 5.57% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 3.70M to 26.06M.

The secondary factor is the Margin Expansion, contributed -99.77%to the performance.

Overall, the performance of ZVRA in the past 1 year is driven by Revenue Growth. Which is more sustainable.

605.36%

3.70M → 26.06M

Revenue Growth

-99.77%

-899.19 → -2.09

Margin Expansion

-511.16%

-3.99 → 16.39

P/E Change

-5.57%